Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $496,080.00 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Richard S. Geary sold 8,268 shares of the business’s stock in a transaction dated Friday, October 13th. The stock was sold at an average price of $60.00, for a total transaction of $496,080.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Ionis Pharmaceuticals, Inc. (IONS) opened at 63.66 on Friday. Ionis Pharmaceuticals, Inc. has a one year low of $24.58 and a one year high of $65.41. The firm has a market cap of $7.92 billion, a PE ratio of 306.06 and a beta of 3.12. The company’s 50-day moving average is $56.15 and its 200-day moving average is $50.31.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The firm’s quarterly revenue was up 170.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.47) EPS. On average, analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.16) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $496,080.00 in Stock” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/10/20/ionis-pharmaceuticals-inc-ions-svp-sells-496080-00-in-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of IONS. BlackRock Inc. raised its holdings in Ionis Pharmaceuticals by 37,569.7% in the 1st quarter. BlackRock Inc. now owns 6,559,808 shares of the company’s stock valued at $263,704,000 after buying an additional 6,542,394 shares during the last quarter. State Street Corp raised its holdings in Ionis Pharmaceuticals by 20.5% during the 1st quarter. State Street Corp now owns 3,340,471 shares of the company’s stock worth $134,285,000 after purchasing an additional 567,792 shares during the last quarter. Vanguard Group Inc. raised its holdings in Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares during the last quarter. Smith Asset Management Group LP bought a new position in Ionis Pharmaceuticals during the 2nd quarter worth approximately $11,394,000. Finally, Gotham Asset Management LLC raised its holdings in Ionis Pharmaceuticals by 227.6% during the 1st quarter. Gotham Asset Management LLC now owns 313,432 shares of the company’s stock worth $12,600,000 after purchasing an additional 217,756 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

A number of brokerages have weighed in on IONS. Stifel Nicolaus boosted their target price on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a research note on Wednesday, August 9th. TheStreet raised shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Evercore ISI began coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $65.00 target price for the company. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $50.04.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

IONS) opened at 63.66 on Friday. Ionis Pharmaceuticals, Inc. has a one year low of $24.58 and a one year high of $65.41. The firm has a market cap of $7.92 billion, a PE ratio of 306.06 and a beta of 3.12. The company’s 50-day moving average is $56.15 and its 200-day moving average is $50.31.

Ionis Pharmaceuticals (NASDAQ:IONS) last issued its quarterly earnings data on Tuesday, August 8th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.03). The business had revenue of $104.15 million during the quarter, compared to the consensus estimate of $93.29 million. Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The firm’s quarterly revenue was up 170.7% compared to the same quarter last year. During the same quarter last year, the business earned ($0.47) EPS. On average, analysts forecast that Ionis Pharmaceuticals, Inc. will post ($0.16) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Ionis Pharmaceuticals, Inc. (IONS) SVP Sells $496,080.00 in Stock” was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://ledgergazette.com/2017/10/20/ionis-pharmaceuticals-inc-ions-svp-sells-496080-00-in-stock.html.

A number of hedge funds and other institutional investors have recently modified their holdings of IONS. BlackRock Inc. raised its holdings in Ionis Pharmaceuticals by 37,569.7% in the 1st quarter. BlackRock Inc. now owns 6,559,808 shares of the company’s stock valued at $263,704,000 after buying an additional 6,542,394 shares during the last quarter. State Street Corp raised its holdings in Ionis Pharmaceuticals by 20.5% during the 1st quarter. State Street Corp now owns 3,340,471 shares of the company’s stock worth $134,285,000 after purchasing an additional 567,792 shares during the last quarter. Vanguard Group Inc. raised its holdings in Ionis Pharmaceuticals by 4.4% during the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares during the last quarter. Smith Asset Management Group LP bought a new position in Ionis Pharmaceuticals during the 2nd quarter worth approximately $11,394,000. Finally, Gotham Asset Management LLC raised its holdings in Ionis Pharmaceuticals by 227.6% during the 1st quarter. Gotham Asset Management LLC now owns 313,432 shares of the company’s stock worth $12,600,000 after purchasing an additional 217,756 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

A number of brokerages have weighed in on IONS. Stifel Nicolaus boosted their target price on shares of Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a research note on Wednesday, August 9th. TheStreet raised shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Wednesday, July 26th. Zacks Investment Research downgraded shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Finally, Evercore ISI began coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $65.00 target price for the company. Three investment analysts have rated the stock with a sell rating, six have given a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $50.04.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply